AI's ability to monitor a warfighter's mental state, visuals or inner dialog may outpace the ability to shield that data from ...

Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities - POTOMAC, MD / ACCESS Newswire / January 12, 2026 / IGC Pharma, Inc. (NYS ...

The breakthrough tackles a longstanding challenge in genetic medicine with the goal of developing a new generation of curative cell and gene therapies.Developed in collaboration with NVIDIA ...

Dewpoint has selected a novel small molecule to prevent the formation of abnormal TDP-43 protein clumps in ALS and other ...

At 71 years old, facing a terminal diagnosis, Colorado resident Tom Pringle has one more thing he wants to do before he dies: help other people in similar situations by trying an experimental drug to ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

At 71 years old, facing a terminal diagnosis, Colorado resident Tom Pringle has one more thing he wants to do before he dies: ...

For adults with amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene, long-term treatment with tofersen (Qalsody, Biogen) was associated with slowed ...

The offering price of $6.50 represents a premium to the current trading price of $5.97. "Their investment further validates the promise and potential of ALS biomarkers and survival data for a planned ...

A breakthrough made in Chicago aims to stop Alzheimer’s disease and ALS in their tracks. Local scientists have spent years investigating the potential of a tiny molecule. Then, in mice, they saw it ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...